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Pyrazoleamide compounds are potent antimalarials
that target Naþ homeostasis in intraerythrocytic
Plasmodium falciparum
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The quest for new antimalarial drugs, especially those with novel modes of action, is essential
in the face of emerging drug-resistant parasites. Here we describe a new chemical class of
molecules, pyrazoleamides, with potent activity against human malaria parasites and showing
remarkably rapid parasite clearance in an in vivo model. Investigations involving pyr-
azoleamide-resistant parasites, whole-genome sequencing and gene transfers reveal that
mutations in two proteins, a calcium-dependent protein kinase (PfCDPK5) and a P-type
cation-ATPase (PfATP4), are necessary to impart full resistance to these compounds.
A pyrazoleamide compound causes a rapid disruption of Naþ regulation in blood-stage
Plasmodium falciparum parasites. Similar effect on Naþ homeostasis was recently reported for
spiroindolones, which are antimalarials of a chemical class quite distinct from pyr-
azoleamides. Our results reveal that disruption of Naþ homeostasis in malaria parasites is a
promising mode of antimalarial action mediated by at least two distinct chemical classes.
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I
t is a well-established fact that microbial pathogens subjected
to drug pressure tend to develop resistance to the drug. The
probability of resistance emergence increases in proportion to
the size of the population exposed to the antimicrobials. With
hundreds of millions of malaria cases being treated with
antimalarial drugs each year and with each individual patient
bearing hundreds of billions of malaria parasites1, it is necessary
to continue to feed the antimalarial pipeline with new drugs to
counter the likely emergence of resistance. The emergence and
spread of chloroquine-resistant Plasmodium falciparum has been
a major contributing factor for the resurgence in malaria
morbidity and mortality during the 1980s and 1990s (ref. 2),
which only now seems to be abating with the advent of
artemisinin combination therapy and other interventions3,4.
Reports of delayed clinical response to artemisinin derivatives
in Southeast Asia as a harbinger of resistance emergence5–7
provide further impetus for the need to have an available robust
antimalarial pipeline. Over the past decade, the Medicines for
Malaria Venture (MMV) has spearheaded efforts of academic and
industrial partners to discover and develop antimalarial drugs.
Several new compounds at various stages of development have
been identified through these efforts8.
We describe here our investigations of a new chemical class of
antimalarial compounds with highly potent activity against
P. falciparum and P. vivax, the most prevalent species causing
human malaria. These compounds are active against parasites
resistant to currently used antimalarials and are also inhibitory to
the onward development of the sexual stages of P. falciparum
indicating their potential to be an effective means for treating
malaria and for its transmission. Genetic and biochemical studies
indicate that the pyrazoleamides are likely to affect a cation-
pumping P-type ATPase, resulting in rapid disruption of Naþ
homeostasis in intraerythrocytic P. falciparum. This mode of
action is similar to a recent demonstration that NITD609 (ref. 9),
an antimalarial spiroindolone under development with a very
different chemical structure, also disrupts Naþ homeostasis in
malaria parasites10.
Results
Pyrazoleamides as potent inhibitors of human Plasmodium
spp. The initial hit compounds C416, a pyrazoleurea derivative,
and C2-1, a pyrazoleamide derivative, (Fig. 1a) were identified
through a structure-based in silico screening of a compound
library11 and showed growth inhibitory activity with effective
concentration for 50% growth inhibition (EC50) of 150 and
50 nM, respectively, against P. falciparum. An extensive medicinal
chemistry campaign (to be described in detail elsewhere) was
conducted by synthesizing variants of pyrazoleamide compound
C2-1 and leading to a series of compounds with low nanomolar
activity against P. falciparum. Structures of three of the late lead
compounds, PA21A050 (EC50: 0.7 nM), PA21A092 (EC50: 5 nM)
and PA21A102 (EC50: 8 nM), are shown in Fig. 1a. On the basis
of its biological, pharmaceutical and toxicological profiles,
compound PA21A092 was designated as a preclinical drug
candidate to be developed for first-in-human studies. Relatively
equal activity of PA21A092 was observed over a 48-h period
against P. falciparum, regardless of the stage of parasites used in
the assay, with EC50 values ranging from 5 to 13 nM (Fig. 1b).
The functional viability of P. falciparum mature Stage V male and
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Figure 1 | Structure and antimalarial activities of pyrazoleamide compounds. (a) Structures of the hit and lead compounds. (b) Growth inhibition
assays of PA21A092 against the indicated stages of Dd2 line of P. falciparum. (c) PA21A092 inhibits male (blue) and female (red) gamete production by mature
gametocytes. EC50 values are estimated to be 39 and 74nM for male and female gamete production, respectively; methylene blue as a positive control had
EC50 values of 39 and 43nM, respectively, in these assays. (d) PA21A092 is active against clinical field isolates of P. falciparum (red circles) and P. vivax (blue
circles) in ex vivo growth inhibition assays with equal potency against ring (closed triangles) and trophozoite (open triangles) stages in both species.
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female gametocytes as manifested by their ability to form male
and female gametes, respectively, was inhibited when exposed to
PA21A092 with an EC50 of 39 and 74 nM, respectively (Fig. 1c),
indicating its potential to act also as a transmission-blocking
drug. A panel of eight P. falciparum lines resistant to a number of
currently used antimalarial drugs were susceptible to compound
21A092 (Supplementary Table 1), suggesting a mode of action
different from currently used antimalarials. Furthermore,
PA21A092 was tested against clinical isolates of P. falciparum
and P. vivax infecting patients living in an area with high
prevalence of multiple drug resistance. Using an ex vivo assay12,
we found that both species were highly susceptible to PA21A092,
with a median EC50 of 18 nM against P. falciparum from 32
patients and 10 nM against P. vivax from 35 patients (Fig. 1d).
In vivo efficacy of pyrazoleamides against P. falciparum. We
used nonobese/severe combined immunodeficiency/IL2Rgnull
(NOD/SCID/IL2Rgnull) mice engrafted with human erythrocytes
and infected with an adapted line of P. falciparum as a model to
assess in vivo efficacy of the pyrazoleamide compounds13,14. This
model has been used previously for examining many different
antimalarials for their in vivo activity against the human malaria
parasite P. falciparum15. Groups of three mice each were treated
once a day for 4 consecutive days, beginning on day 3 post
infection, with four oral dose levels of PA21A092. As shown in
Fig. 2a, PA21A092 was highly effective when administered orally
with effective dose for 90% parasitemia reduction (ED90) of
2.5mg kg 1. Compound PA21A050 had ED90 of 0.9mg kg 1
(Supplementary Fig. 1), whereas PA21A102 had an ED90 of
4mg kg 1 (Supplementary Fig. 2). The pharmacokinetics of
PA21A092 in the mice employed in the therapeutic efficacy study
was studied by taking 25 ml serial blood samples up to 23 h after
the first dose. As shown in Fig. 2b and Supplementary Table 2,
oral pharmacokinetics were approximately linear in the dose
range used. Assuming no significant accumulation during
treatment, the estimated drug exposure necessary to inhibit
P. falciparum parasitemia on day 7 post infection by 90% with
respect to control mice (area under the curve at 90% effective
dose, AUCED90) was 0.24 mg hml 1 per day (Fig. 2c). In this
in vivo assay, the AUCED90 is the average daily exposure necessary
to achieve no net parasite growth on day 7. The maximum
parasite clearance was achieved at PA21A092 blood exposure of
above 1 mg hml 1 per day and was comparable, in this model, to
that seen with artesunate, which is thus far the fastest-acting
antimalarial in use. Erythrocytes with only remnants of parasite
nuclei were seen following 2-day treatments with the pyrazole
compounds (Fig. 2d,e).
Investigating P. falciparum resistant to pyrazoleamides. The
lack of cross-resistance to the pyrazoleamides in parasites resis-
tant to currently used antimalarial drugs suggests a potentially
novel mode of action for this new chemical class. To gain
mechanistic insight into the action of the pyrazoleamides, we
derived P. falciparum lines resistant to the initial hit compound
C2-1. Our assessment of resistance frequency for compounds
PA21A050 and PA21A092 indicated a rate of o3 10 9 under
a standard protocol16 of continuous exposure to 10 EC50
concentration of the compounds, suggesting a low propensity for
parasite resistance development against these compounds.
Therefore, resistant parasite lines were derived by exposure of
the Dd2 line of P. falciparum to 3 EC50 concentration of the
compound C2-1. Three lines resistant to compound C2-1 with an
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Figure 2 | In vivo efficacy of PA21A092 against P. falciparum. Four indicated doses of PA21A092 were administered orally to groups of three NOD/scid/
IL2Rgnull mice each engrafted with human erythrocytes and infected with P. falciparum. The compound was administered starting on day 3 post infection
for 4 consecutive days. Parasitemia was assessed each day from day 3 post infection up to 7 days (a). Concentrations of PA21A092 were measured
by LC/MS in each mouse at 0.25, 0.5, 1, 2, 4, 7, 10 and 23 h after the first dose (b). The estimated drug exposure necessary to inhibit P. falciparum
parasitemia on day 7 post infection by 90% (AUCED90) was 0.24mg hml 1 per day 1 (c). Comparison of morphology of parasitized human RBC
(as observed in Giemsa-stained thin blood smears prepared on day 7 after infection) in vehicle-treated (d) and PA21A092-treated (e) mice revealed
normal stages of parasites in control but erythrocytes with only highly pyknotic staining nuclei fragments in treated mice (scale bars, 10mm). In a–c, each
symbol represents individual mouse with the dose of compound indicated in the inset on the right. Open circles in a are mice treated with the vehicle only.
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EC50 of B20-fold higher than the wild-type parasites were
derived through this process of exposure to a reduced level of the
compound (Supplementary Fig. 3). These resistant parasites were
cross-resistant to all active pyrazoleamide compounds, including
the late lead and candidate compounds (Supplementary Table 3),
suggesting a common mode of action for the pyrazoleamide
series.
To gain insight into the mode of action for and resistance to
the pyrazoleamides, genomes of the Dd2 parental line and the
three pyrazoleamide-resistant lines were sequenced using ‘next-
generation’ sequencing technology17. Custom-designed
bioinformatics for P. falciparum genome-sequence comparison18
revealed non-synonymous single-nucleotide polymorphism (SNP)
in five genes: PF3D7_0411900, DNA polymerase alpha (mutation
D133Y); PF3D7_0630900, DEAD/DEAH box ATP-dependent
RNA helicase (N142K, a polymorphic site); PF3D7_1034300,
thioredoxin-like associated protein 2, (K465E); PF3D7_
1211900, non-SERCA calcium ATPase (V178I); and PF3D7_
1337800, calcium-dependent protein kinase 5 (T392A). These
mutations were common to all three resistant lines compared with
the parental Dd2 parasites. An assessment of potential effects of
these mutations as well as expression patterns of these genes led us
to focus initial attention on two proteins: the calcium-dependent
protein kinase 5 (PfCDPK5; PF3D7_1337800) and a P-type cation
ATPase annotated as a non-SERCA calcium ATPase, PfATP4
(PF3D7_1211900). Dvorin et al.19 have shown PfCDPK5 to be
essential for egress of progeny merozoites at the last step of
erythrocytic schizogony by P. falciparum, and thus deemed an
attractive drug target. The resistance-associated mutation, T392A,
in PfCDPK5 was predicted to be in the junction region of the
enzyme that links the kinase domain to the calmodulin-like
EF-hand domains, and acts as a regulatory loop of the enzyme
(Fig. 3a). PfATP4 was first described as a Ca2þ pump20,21 and
recently found to bear mutations in P. falciparum parasites resistant
to a new class of antimalarials, the spiroindolones9. Spillman et al.10
have provided evidence consistent with the hypothesis that PfATP4
is a P-type Naþ ATPase and a target for the spiroindolones. The
resistance-associated mutation in PfATP4, a conservative V178I
change, was localized to the predicted first transmembrane domain
of the protein (Fig. 3b), and was different from the mutations
observed by Rottmann et al.9 in spiroindolone-resistant parasites.
The pyrazoleamide-resistant lines described here were not cross-
resistant to a spiroindolone (Supplementary Fig. 3b).
Mutations necessary for full resistance to pyrazoleamides. To
assess the effects of expressing the mutated version of the enzyme
(PfCDPK5T392A), a transgenic Dd2 line of P. falciparum was
constructed in which the PfCDPK5wt allele was replaced by
PfCDPK5T392A allele via single crossover allelic exchange
recombination (Supplementary Fig. 4). When this transgenic
parasite line (Dd2::PfCDPK5T392A) was examined for its response
to pyrazoleamide compounds, it was found to have a slightly
higher EC50 value compared with its parental line (Table 1 and
Supplementary Fig. 5), showing that the PfCDPK5T392A allele by
itself appeared to result in a rather modest level of resistance to
the pyrazoleamide compounds. We also derived transgenic Dd2
lines expressing either the PfATP4wt or PfATP4V178I allele from
an ectopic site using a Mycobacteriophage recombination
system22. Western blot analysis of transgenic parasites indicated
relatively equal expression of the PfATP4 transgene
(Supplementary Fig. 6). As shown in Table 1 and
Supplementary Fig. 5, Dd2 parasites expressing PfATP4wt
responded to compound PA21A050 with an EC50 similar to the
parental Dd2 line, whereas transgenic Dd2 line expressing
PfATP4V178I allele showed EC50 about twofold higher than the
parental line. This indicated a slight gain of resistance by the
transgenic parasites expressing PfATP4V178I allele in a
merodiploid state; however, the degree of resistance was much
lower than that observed in the original resistant line. At this
point, we used the Dd2::PfCDPK5T392A line as the recipient of the
wild-type or the mutant alleles of PfATP4 through transfection.
Whereas there was no change in the EC50 value for the
compound PA21A050 in the Dd2::PfCDPK5T392A line
expressing PfATP4wt allele, a resistance level similar to the
original resistant line was observed in the Dd2::PfCDPK5T392A
line expressing the PfATP4V178I allele (Table 1 and
Supplementary Fig. 5). The transgenic parasites bearing double
mutations were also resistant to several different pyrazoleamide
compounds (Table 1 and Supplementary Fig. 5). These results
strongly support the contention that a combined activity of
mutated alleles of both PfCDPK5 and PfATP4 is necessary
to impart full resistance to pyrazoleamide compounds in
P. falciparum.
A pyrazoleamide disrupts Naþ homeostasis in P. falciparum.
As highlighted in a recent study10, PfATP4 bears a close
resemblance to the closely related ENA (exitus natrum) Naþ
ATPases that extrude Naþ ions from the cells of fungi and lower
plants23. In the same study it was shown that antimalarial
spiroindolones at therapeutic doses rapidly disrupt Naþ
homeostasis in blood-stage P. falciparum parasites, and that
spiroindolone-resistant parasites with mutations in PfATP4
(ref. 9) had reduced sensitivity to disruption of Naþ
homeostasis by a spiroindolone10. As shown in Fig. 4a, the
pyrazoleamide PA21A050 treatment of saponin-isolated parasites
led to rapid increase in intracellular Naþ concentration
([Naþ ]i), doing so in a dose-dependent manner. Remarkably, a
maximum initial Naþ influx rate ofB0.07mM s 1 was reached
with the addition of just 1 nM PA21A050 (Fig. 4b). The increase
in [Na]i was accompanied by an increase in intracellular pH
(pHi, Fig. 4c), whereas there was no significant change in
intracellular Ca2þ ([Ca2þ ]i) on addition of PA21A050 (Fig. 4d).
These results are similar to those reported for the
spiroindolones10 except that PA21A050 was more potent in its
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Figure 3 | Mutations in compound C2-1-resistant parasites. A Thr to Ala
mutation at position 392 in PfCDPK5 is in its predicted junction domain (a),
and a Val to Ile mutation at position 178 in PfATP4 (b) is in the first
predicted transmembrane domain.
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activity in this assay. Antimalarials such as artesunate and
chloroquine have no effect on [Naþ ]i in this assay10.
As P. falciparummatures from the ring stage to the trophozoite
stage, new permeability pathways (also called Plasmodial-surface
anion channels, or PSAC) are established in the erythrocyte
membrane resulting in an increased permeability to a diverse
range of low molecular weight solutes24,25. One consequence of
this is an increase in [Naþ ] inside the erythrocyte cytosol26 and,
hence, an inward [Naþ ] gradient across the plasma membrane of
the intraerythrocytic trophozoite.
We examined the effect of PA21A050 on P. falciparum
development by time-lapse live cell imaging in erythrocytes
starting from ring-stage parasites (Supplementary Movies 1 and 2).
Ring-stage parasites progressed to develop into trophozoites while
being exposed to PA21A050. At the late trophozoite stage
there was visible increase in volume of the parasite, which was
followed by dramatic apparent bursting; schizogony or mero-
zoites were not observed (Supplementary Movie 2; notice swelling
and bursting from 2,400 to 2,600min time frames). These
observations are consistent with the proposition that pyrazolea-
mides disrupt Naþ homeostasis, the effect of which becomes
apparent coincident with the rise in [Naþ ] within the infected
erythrocyte cytoplasm at the trophozoite stage. An increase in
[Naþ ] in the parasite cytoplasm is predicted to give rise to an
associated osmotic uptake of water and an associated swelling. To
assess the extent of swelling, we measured the diameter of
trophozoite-stage parasites in intact infected erythrocytes after 2 h
of exposure to PA21A050 in still images of a number of parasites.
Table 1 | Efficacy of pyrazoleamides and a spiroindolone in transgenic P. falciparum.
Parasite line In vitro EC50, nM (±s.e.m.)
PA21A050 PA21A092 PA27-X41 NITD246
Dd2 0.7 (±0.2) 12.9 (±2.0) 0.7 (±0.15) 0.15 (±0.01)
Dd2-R21 16 (±0.5) 133 (±8.0) 122 (±10) 0.21 (±0.04)
Dd2::PfCDPK5T392A 1.5 (±0.1) 23 (±3.0) ND 0.17 (±0.04)
Dd2attBþ PfATP4wt 0.5 (±0.1) 22 (±9.0) 2 (±0.4) 0.34 (±0.08)
Dd2attBþ PfATP4V178I 2 (±0.3) 34 (±2.6) 17.4 (±4.0) 0.19 (±0.04)
Dd2::PfCDPK5T392Aþ PfATP4wt 0.8 (±0.07) 31 (±3.5) 2 (±0.01) 0.36 (±0.09)
Dd2::PfCDPK5T392Aþ PfATP4V178I 11 (±0.5) 176 (±8.0) 274 (±17) 0.62 (±0.07)
EC50, effective concentration for 50% growth inhibition; ND, not done.
EC50 values for three pyrazoleamides and a spiroindolone (NITD246) were derived from growth inhibition assays for Dd2 and a compound C2-1-resistant line, as well as five other transgenic lines derived
from Dd2 parent. Growth inhibition curves are shown in Supplementary Fig. 5.
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As shown in Fig. 5, the average diameter of the treated
trophozoite stage increased to 4.6 mm in 2 h compared with
2.5 mm in untreated control trophozoites from the same culture,
consistent with the parasite having undergone significant
swelling.
Reduced sensitivity of parasites in low [Naþ ] medium. The
results described above suggest that a contributing factor for
antimalarial properties of these compounds could be toxicity
associated with high [Naþ ]i. Recently, Pillai et al.27 have
elegantly demonstrated that P. falciparum can tolerate a broad
range of [Naþ ] in growth medium as long as appropriate
osmotic conditions are maintained by KCl and sucrose. We took
advantage of the low [Naþ ] growth medium used by Pillai et al.27
to ask whether parasites grown under low [Naþ ] condition had
altered responses to antimalarial compounds that disrupt Naþ
homeostasis. As shown in Table 2, Dd2 line of P. falciparum
showed three- to fivefold reduced susceptibility to both the
pyrazoleamide and spiroindolone compounds when grown in low
[Naþ ] medium. It was interesting to note that the reduced
susceptibility was more pronounced in a Dd2-21R line that was
derived as resistant to a pyrazoleamide compound. These results
further support the notion that Naþ homeostasis disruption is a
key component of antimalarial action of these two chemically
distinct classes of compounds.
Discussion
We have described a multinational collaborative effort that has
delivered a new chemical entity as a candidate antimalarial drug
worthy of being developed for clinical investigations. Potent
inhibitory activity of pyrazoleamides against multiple isolates of
P. falciparum as well as P. vivax suggests the potential of
deploying these compounds as part of a malaria control and
elimination strategy. An added attractive feature of these
compounds is their activity against the mature sexual stages of
P. falciparum, a property not common to most of the currently
used antimalarial drugs. Inhibition of gamete production by these
compounds would prevent parasite mating and transmission by
mosquitoes, a goal that has to be part of a malaria elimination
programme. Results from in vivo efficacy studies described here
demonstrate rapid clearance of P. falciparum when exposed to
orally administered pyrazoleamides. This rate of clearance is
reminiscent of clearance by artemisinin derivatives, which are the
fastest-acting antimalarials in clinical use.
We provide evidence suggesting rapid disruption of Naþ
homeostasis in intraerythrocytic parasites as a consequence of
exposure to pyrazoleamides at pharmacologically relevant con-
centrations. It has been shown previously that the induction by
the parasite of new permeability pathway/Plasmodial-surface
anion channel in erythrocyte plasma membrane occurs as the
ring-stage parasite transitions to the metabolically more active
trophozoite stage24,25. As a consequence, [Naþ ] inside the
erythrocyte cytoplasm increases24,25, yet [Naþ ] inside the
parasite remains physiologically low. Spillman et al.10 have
suggested that the maintenance of low [Naþ ]i inside the parasite
is mediated by a P-type Naþ ATPase pump encoded by the
parasite, and that the new antimalarial spiroindolone, NITD246,
interferes with the activity of this pump leading to a rapid net
uptake of Naþ . We show here that a pyrazoleamide has a similar
effect to the spiroindolones on Naþ influx in saponin-isolated
parasites. Furthermore, we show that just a 2-h exposure to a
pyrazoleamide results in a significant increase in the volume of
intact intraerythrocytic trophozoite-stage parasites, followed by a
dramatic bursting of the parasite. These results, in combination
with our observation of reduced efficacy of the pyrazoleamide and
spiroindolone against P. falciparum parasites growing under low
[Naþ ] conditions, provide strong evidence that these two
chemically distinct classes of compounds share a common
mode of action through disruption of Naþ homeostasis.
The finding that mutations in PfATP4 are associated with
acquisition of resistance to spiroindolone and pyrazoleamide
compounds is consistent with the hypothesis that this P-type
ATPase is a direct target of these compounds. However, some
caution is warranted. A mutation in PfCDPK5, which by itself
imparts minimal resistance to pyrazoleamides, greatly enhances
6.0 P<0.001
n=35n=35
2 µm
2 µm
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Control Pyrazole
Treatment
D
ia
m
et
er
 (µ
m
)
Figure 5 | PA21A050 causes swelling of intraerythrocytic P. falciparum.
Live cell images of trophozoite stages were obtained at 2 h from untreated
and PA21A050-treated parasites attached to a glass-bottom Petri plate by a
Nikon microscope equipped with an incubation chamber for regulating
temperature and gas mixture. The diameter of the indicated number of
parasites were measured from the images using the ImageJ software. Error
bars indicate s.d.
Table 2 | Efficacy of antimalarials on P. falciparum grown in low [Naþ ] medium.
Compound P. falciparum line EC50 in normal [Na
þ ] medium, nM (±s.e.m.) EC50 in low [Naþ ] medium, nM (±s.e.m.)
PA21A050 Dd2 0.5 (±0.01) 2.7 (±0.3)
PA21A085 Dd2 5.7 (±0.3) 19 (±0.9)
PA21A085 Dd2-21R 221 (±20) 45,000
NITD246 Dd2 0.5 (±0.03) 1.8 (±0.1)
NITD246 Dd2-21R 0.7 (±0.02) 3.3 (±0.15)
Artemisinin Dd2 11 (±0.4) 7 (±0.13)
EC50, effective concentration for 50% growth inhibition.
Growth inhibition assays were carried out for Dd2 and a compound 2-1 resistant line (Dd2-21R) using the indicated pyrazoleamide and a spiroindolone. The assays were carried out either in the normal
growth medium or in a low [Naþ ] medium described in ref. 27.
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the level of resistance in combination with mutated PfATP4.
PfCDPK5 has been shown to be essential in the very last step of
schizogony before merozoites egress19. It has also been shown
that mature schizont-stage parasites undergo swelling just before
merozoite egress, and this is thought to facilitate the egress
process28. The finding in this study of an association between
PfATP4 and PfCDPK5 raises the possibility that the swelling is the
result of increased Naþ influx, perhaps because of inhibition of
PfATP4 activity, resulting from a cascade of events in which
PfCDPK5 plays a regulatory function. Under this scenario, it
might be envisioned that pyrazoleamides (and possibly
spiroindolones) act as premature signals to initiate an egress-
like cascade resulting in Naþ influx and swelling.
Further experiments are needed to understand details of events
that lead to the demise of the parasites exposed to these new
antimalarials. It is clear, however, that observations reported here
are hinting at a hitherto unknown pathway in malaria parasites,
which can be interfered with by at least two different classes of
chemicals. Recent observations from our and other laboratories
suggest additional compounds of unrelated chemical structures
may also target this pathway. We look forward to unravelling
mechanistic details of this pathway with a view to discovering
other new antimalarial drugs.
Methods
Synthesis schemes for pyrazoleamides. All reagents and starting materials
described in the procedures are commercially available and were used without
further purification. Synthetic route for N-(4-(4-chloro-2-fluorophenyl)-3-(tri-
fluoromethyl)-1-methyl-1H-pyrazol-5-yl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-
yl)acetamide (Compound PA21A050) is illustrated in Fig. 6. To a mixture of 2-(2-
isopropyl-1H-benzo[d]imidazol-1-yl)acetic acid (0.16mmol) and Mukaiyama’s
reagent (2-chloro-1-methylpyridinium iodide, 0.38mmol) in 1.5ml anhydrous
dichloromethane (DCM), 4-(4-chloro-2-fluorophenyl)-3-(trifluoromethyl)-1-
methyl-1H-pyrazol-5-amine (0.12mmol), triethylamine (0.40mmol) and 0.5ml of
anhydrous tetrahydrofuran were added. The mixture was vortexed and subjected to
microwave irradiation for 30min at 75 C to give a deep-green clear solution. Then
80ml of ethyl acetate was added and the solution was washed with 80ml of
saturated NaHCO3 twice, and with brine, and then dried over MgSO4. After solvent
removal and purification on a flash silica gel column using ethyl acetate and hexane
as eluent, a slightly brown-coloured solid was obtained. After recrystallization in
ethyl acetate/hexane, 45mg of Compound PA21A050 was obtained as a white
powder. Yield: 76%. Purity:495% by HPLC (UV at 220 nm). 1H NMR (500MHz,
MeOD) d 7.81–7.83 (m, 1H), 7.60–7.70 (m, 3H), 7.26–7.36 (m, 3H), 5.54 (s, 2H),
3.92 (s, 3H), 3.50–3.55 (m, 1H), 1.50 (d, J¼ 6.9Hz, 6H). 13C-NMR (126MHz,
MeOD) d 169.30, 162.35, 162.02, 160.36, 142.93, 136.64, 136.55, 136.24, 134.19,
125.84, 123.87, 123.59, 119.31, 117.68, 117.60, 117.56, 117.39, 110.42, 46.39, 37.06,
27.47, 21.81. high-resolution mass spectrometry, electrospray ionisation
(HRMS(ESI)): M/Z calculated for C23H20ClF4N5OþHþ [MþHþ ]: 494.1365.
Found: 494.1358. Traces of liquid chromatography/mass spectrometry (LC/MS),
1H NMR and 13C-NMR of PA21A050 are shown in Supplementary Figs 7 and 8.
Synthetic route for N-(4-(4-chloro-2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-
5-yl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)acetamide (Compound
PA21A092) is illustrated in Fig. 6. The synthesis followed the route for PA21A050
described above using 4-(4-chloro-2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-
amine (0.12mmol) as starting material. After silica gel chromatography using ethyl
acetate and hexane as eluent, 42mg of Compound PA21A092 was obtained as a
white powder. Yield: 80%, purity: 495% by HPLC (UV at 220 nm). 1H NMR
(500MHz, MeOD) d 7.62–7.64 (m, 1H), 7.23–7.33 (m, 6H), 5.15 (s, 2H), 3.73 (s,
3H), 3.18–3.21 (m, 1H), 2.17 (s, 3H), 1.39 (d, J¼ 6.8Hz, 6H). 13C-NMR (126MHz,
MeOD) d 169.25, 162.16, 162.04, 160.18, 147.16, 142.89, 136.24, 134.90, 133.76,
125.92, 123.80, 123.56, 119.25, 117.67, 117.46, 110.51, 110.31, 46.39, 35.79, 27.46,
21.82 and 12.67. HRMS (ESI): M/Z calculated for C23H23ClFN5OþHþ
[MþHþ ]: 440.1648. Found: 440.1641. Traces of LC/MS, 1H NMR and 13C-NMR
of PA21A092 are shown in Supplementary Figs 9 and 10.
Synthetic route for (R)-3-amino-4-(4-fluorophenyl)-N-(4-(4-fluorophenyl)-1,3-
dimethyl-1H-pyrazol-5-yl)butanamide (Compound PA21A102) is illustrated in
Fig. 6. To a solution of Fmoc-(R)-3-amino-4-(4-fluorophenyl)butanoyl chloride
(43mg, 0.20mmol) produced from Fmoc-(R)-3-amino-4-(4-fluorophenyl)butanoic
acid and thionyl chloride in 10ml of anhydrous DCM were slowly added 4-(4-
fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine (31mg, 0.15mmol) in 5ml of
anhydrous DCM. The reaction mixture was stirred at room temperature overnight.
The reaction mixture was quenched with methanol and solvents were removed.
The residue was purified via silica gel with MeOH/DCM to obtain Fmoc-protected
product. Fmoc-protected product was dissolved in 10ml of ethyl acetate and
0.20mmol of 1,8-diazabicyclo[5.4.0]undec-7-ene) in ethyl acetate was added. After
20min, 20ml of ethyl acetate was added and the mixture was washed with 20ml of
water. The organic layer was collected and solvent was removed. The residue was
dissolved in MeOH and acidified with 0.2N HCl. The solution was purified via
preparatory RP-HPLC, eluting with H2O/CH3CN gradient (þ 0.05%
trifluoroacetic acid, TFA). Product fractions were collected and concentrated. The
residue was dissolved in a small amount of 2M HCl in methanol and, after
concentration in vacuo, 48mg of Compound PA21A102 was obtained as an HCl
salt. Yield: 76%. Purity: 495% by HPLC (UV at 220 nm). To prepare the
compound as free base, the salt form was dissolved in saturated Na2CO3 solution
and extracted with ethyl acetate followed by removal of solvent. 1H NMR of free
base form (500MHz, MeOD) d 7.30–7.32 (m, 2H), 7.20–7.22 (m, 2H), 7.11–7.15
(m, 2H), 7.03–7.07 (m, 2H), 3.68 (s, 3H), 3.38–3.44 (m, 1H), 2.72–2.76 (m, 1H),
2.62–2.66 (m, 1H), 2.51–2.55 (m, 1H), 2.37–2.42 (m, 1H), 2.24 (s, 3H). 13C-NMR
(126MHz, MeOD) d 174.60, 164.17, 162.23, 146.13, 135.61, 135.58, 134.56, 132.06,
131.99, 131.90, 131.84, 129.70, 116.44, 116.31, 116.27, 116.14, 51.07, 43.28, 42.56,
35.57 and 12.78. HRMS (ESI): M/Z calculated for C21H22F2N4OþHþ [MþHþ ]:
385.1834. Found: 385.1832. Traces of LC/MS, 1H NMR and 13C-NMR of
PA21A102 are shown in Supplementary Figs 11 and 12.
Parasites and growth inhibition assays. P. falciparum lines (obtained from
Malaria Research and Reference Reagent Resource Center, http://www.mr4.org)
were cultured under standard conditions in RPMI1640 medium supplemented
with 0.5% Albumax in 90% N2, 5% O2 and 5% CO2. Parasite growth inhibition was
assessed by a modified version of the method originally described in ref. 29. The
method assessed parasite growth as reflected by incorporation of 3H-hypoxanthine
by parasites. P. falciparum parasites in culture were exposed to graded dilutions of
test compounds for 48 h and incorporation of 3H-hypoxanthine over the last 24 h
into parasite nucleic acids was determined by liquid scintillation spectroscopy. The
dose–response data were analysed using nonlinear regression analysis (Prism
GraphPad), and the EC50 was derived using an inhibitory sigmoid maximum effect
(Emax) model. For assessing parasite growth inhibition under low [Naþ ] condi-
tions, we used the medium composition designated 4suc:6 KCl as described in ref.
27. Briefly, the medium contained all ingredients specified for RPMI16040 except
that NaCl, NaHCO3 and Na2HPO4 were replaced by 64.8mM KCl, 28.6mM KCO3
and 5.64mM K2HPO4. In addition, 84.3mM sucrose was included in the medium.
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Figure 6 | Synthetic schemes and reaction conditions for
pyrazoleamides. (a) For PA21A050 and PA21A092: 2-(2-isopropyl-1H-
benzo[d]imidazol-1-yl)acetic acid, Mukaiyama’s reagent (2-chloro-1-
methylpyridinium iodide), triethylamine, in dichloromethane/
tetrahydrofuran, microwave, 75 C, 30min. (b) For PA21A102: (i) Fmoc-
(R)-3-amino-4-(4-fluorophenyl)butanoyl chloride in dichloromethane,
(ii) DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) in ethyl acetate.
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Addition of 10% human serum to the 4suc:6 KCl medium was estimated to result
in B7mM Naþ concentration in this medium. Efficacy of compounds to inhibit
parasite growth in the low [Naþ ] 4suc:6 KClþ 10% human serum medium was
assessed in parallel with that in standard RPMI1640 medium by 3H-hypoxanthine
incorporation as described above.
Dual P. falciparum male and female gamete formation assays. A recently
reported assay was used to assess effects of various doses of PA21A092 on gamete
production by the NF54 line of P. falciparum30. P. falciparum NF54 strain
gametocytes were produced by standard methods. Briefly, asexual parasites in the
log phase of growth were passaged to 1% parasitemia/4% haematocrit and cultured
in RPMI mediumþ 25mM HEPESþ 50mg l 1 hypoxanthineþ 2 g l 1 sodium
bicarbonateþ 10% human serum with daily medium changes while maintaining
37 C and 3% O2/5% CO2/92% N2 at all times. Under these conditions, gamete
formation is maximal by 14 days in culture and the assay performed. Cultures were
divided into 200-ml microcultures containing test compound dilutions with no
more than 0.5% dimethylsulphoxide. After 24 h incubation with the test compounds,
gamete formation was stimulated by addition of 2.5mM xanthurenic acid. At 20min,
exflagellation was recorded by time-lapse microscopy using  10 objective and
quantified using a custom algorithm. At 24 h post addition of xanthurenic acid, a
Cy3-labelled anti-Pf25 antibody was added at 1:2,000 dilution to the cultures that
specifically stains female gametes that were then recorded by fluorescence
microscope using a  20 objective and quantified using a custom algorithm.
Percent inhibition of male or female gamete formation was calculated with
respect to the positive (10 mM methylene blue) and negative (DMSO) controls and
the whole assay was repeated four times using independent cultures.
Assessing in vivo efficacy. Efficacy of pyrazoleamides was examined in 10- to
12-week-old female NOD/scid/IL2Rgnull mice engrafted with human erythrocytes
and infected with an adapted P. falciparum line as described previously13,14. Briefly,
three mice per group were inoculated intravenously with 2 107 parasitized
erythrocytes (P. falciparum strain 3D70087/N9 adapted for in vivo growth).
Beginning from day 3 after the inoculation, mice were administered the stated
doses of the compound orally for 4 consecutive days. Chloroquine at 2.5, 5 and
10mg kg 1 was used as a positive control. A group of infected mice given oral
dosing of the vehicle serves as the control. Parasitemia was measured from days 3
to 7 after infection by flow cytometry, counting 106 events. SYTO-16 was used for
staining parasite nucleic acids, and non-cytolytic antimouse erythrocyte
monoclonal antibody Ter-119 conjugated with phycoerythrine was used for
differentiating mouse and human erythrocytes. Thin smears of blood stained with
Giemsa were examined and representative infected erythrocytes photographed on
days 5 and 7 after infection in each mouse. Animal experiments were performed at
the Association for Assessment and Accreditation of Laboratory Animal Care
International-accredited GlaxoSmithKline Laboratory Animal Science facility in
Tres Cantos (Madrid, Spain). All the experiments were approved by the
GlaxoSmithKline Diseases of the Developing World Group Ethical Committee.
Pharmacokinetics of PA21A092 in NOD/SCID/IL2Rcnull mice. The levels of
PA21A092 in blood upon oral administration were measured for all the mice and
dosing levels included in the efficacy study. Serial samples of peripheral blood
(25 ml) were taken at 0.25, 0.5, 1, 2, 4, 7, 10 and 23 h after the first administration of
PA21A092, mixed with 25ml of water for erythrocyte lysis and immediately frozen
and stored at  80 C until analysis. Protein precipitation by liquid–liquid
extraction was performed in a 96-well plate with filter system (MultiScreen Sol-
vinert 0.45 mm Hydrophobic PTFE; Millipore). Briefly, 120 ml of AcN:MeOH
(80:20; v-v) containing internal standard were added to 10 ml of blood/saponin
lysate sample per well. The plates were vortexed for 10min, filtrated and the
filtrates were analysed using LC-MS/MS in positive ion mode with electrospray
(Sciex API 4000 Triple Quadrupole Mass Spectrometer, Sciex, Division of MDS
Inc., Toronto, Canada). Noncompartmental analysis was performed using Phoenix,
version 6.3. (Phoenix WinNonlin Copyright 1998–2012, Certara L.P.) and the main
pharmacokinetic parameters were estimated. Additional statistical analysis of the
data was performed with GraphPad Prism Version 5.01 (GraphPad Software Inc.,
San Diego CA).
Testing in field isolates of P. falciparum and P. vivax. Plasmodium spp. isolates
were collected from patients with malaria attending outpatient clinics in Timika
(Papua Province, Indonesia), a region highly prevalent for multidrug-resistant
strains of P. vivax and P. falciparum. Patients with symptomatic malaria were
recruited into the study if singly infected with P. falciparum or P. vivax and a
parasitaemia of between 2,000 and 80,000ml 1. After written informed consent
was obtained, venous blood (5ml) was collected by venepuncture. Ethical approval
for this project was obtained from the Human Research Ethics Committee of the
Northern Territory Department of Health & Families and Menzies School of
Health Research (HREC 2010-1396), Darwin (Australia) and the Eijkman Institute
Research Ethics Commission (EIREC-47), Jakarta (Indonesia). Plasmodium drug
susceptibility was measured using a protocol modified from the World Health
Organization microtest as described previously12. Two hundred microlitres of a 2%
haematocrit blood medium mixture, consisting of RPMI1640 medium plus 10%
ABþ human serum (P. falciparum) or McCoy’s 5A medium plus 20% ABþ
human serum (P. vivax), were added to each well of predosed drug plates
containing 11 serial concentrations (twofold dilutions) of the compound
PA21A092. A candle jar was used to mature the parasites at 37.0 C for 32–56 h.
Incubation was stopped when 440% of ring-stage parasites had reached the
mature schizont stage (that is, four or more distinct nuclei per parasite) in the
drug-free control well.
Thick blood films made from each well were stained with 5% Giemsa solution
for 30min and examined microscopically. The number of schizonts per 200 asexual
stage parasites was determined for each drug concentration and normalized to that
of the control well. The dose–response data were analysed using nonlinear
regression analysis (WinNonLn 4.1; Pharsight Corporation), and the EC50 was
derived using an Emax model.
Derivation of resistant parasites. P. falciparum line Dd2 was used to derive
parasite lines resistant to the initial hit pyrazoleamide compound C2-1. Three
flasks each containing 108 parasitized erythrocytes were continuously exposed to
3EC50 concentration of the compound with medium changes each day and fresh
provision of human red blood cell (RBC) once a week. Emergence of parasites was
monitored by examining stained thin smears. Each of the flasks yielded resistant
parasites, which were confirmed to be resistant to pyrazoleamides.
Whole-genome sequencing and analysis. Parental Dd2 P. falciparum line and
the three pyrazoleamide-resistant lines were sequenced using the Illumina GAII
and the amplification-free methodology17. From each clone, 300-bp fragments of
genomic DNA were prepared by focused sonication. An individual sequencing
lane was used to produce 33–40 million paired 76-base reads for each sample.
Between 55 and 71% of sequencing reads for each sample mapped uniquely to the
P. falciparum clone 3D7 reference genome, with read-spacing accurately reflecting
the expected fragment size.
Dd2 reads were aligned to the 3D7 genome and any single-base differences or
small indels were identified by iCORN18 to iteratively change the 3D7 sequence
into the one that more closely resembled the actual sequence for Dd2 (hereafter
termed Dd20). Only sequence differences within regions of 10–15 read coverage
were accepted to minimize the possibility of using incorrectly mapped sequences,
and iCORN was run for 17 iterations (until no further sequence differences could
be found between the gene sequences of 3D7 and Dd2). In all, 41,841 base
substitutions were made and 16,638 indels corrected.
Reads from each derived line were mapped to the Dd20 reference to identify
SNPs and indels, using three iterations of iCORN so that SNPs or indel could be
identified even within polymorphic loci. Sequence variants were only identified
within regions of at least  40 coverage on Dd20 . Using a custom Perl script,
genes were identified where a variant was found within the reads for all three
derived clones. Five SNPs were found at the same base position in each of the
three derived clones. These were the only differences observed when compared
with Dd20 .
Approaches to generate transgenic parasites. A DNA fragment corresponding
to nucleotides 9–1,704 of the coding region of PfCDPK5 (PlasmoDB ID
PF3D7_1337800) and having a 50-SpeI site and an in-frame BsiWI site was
amplified using Vent DNA polymerase (New England Biolabs) and cloned into
pCR-Blunt (Invitrogen). The DNA sequence of the amplified fragment was con-
firmed. The PfCDPK5T392A mutation was introduced into the plasmid using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene). The resulting SpeI-BsiWI
DNA fragments were cloned into the P. falciparum vector pCC1-3HA and used to
transform parasite strain Dd2. WR99210-resistant parasites were obtained, sub-
jected to one drug-off/drug-on cycle to select for transgene insertion. The site-
specific integration was confirmed with PCR using both gene-specific and inte-
gration-specific primers, as illustrated in Supplementary Fig. 4. The primers cor-
respond to the following DNA regions: 50-primer ( 425 to  401 nucleotides
upstream of the ATG codon); 30-primer (þ 96 to þ 123 nucleotides downstream
of the Stop codon); C primer (nucleotides 1,671–1,704 of the coding sequence);
3HA primer corresponds to the influenza virus hemagglutination antigen epitope.
Full-length PfATP4 gene was amplified by PCR using genomic DNA from
either the wild-type Dd2 parasite (to produce PfATP4wt), or Dd2-R21 parasites
resistant to compound C2-1 (to produce PfATP4T392A). DNA sequences were
confirmed and the genes were cloned into the pLN plasmid22 to be expressed under
the calmodulin promoter22. Transfections of P. falciparum parasites were carried
out as described elsewhere31,32. Briefly, ring-stage parasites at 5% parasitemia were
electroporated with 50mg plasmid DNA isolated using the Qiagen Plasmid Maxi
Kit. Electroporation was conducted using a Bio-Rad GenePulser set at 0.31 kV and
960 mF. Two aliquots of DNA were electroporated for each transgene. Transfected
parasites were maintained under drug pressure: 5 nM WR99210 for hdhfr (human
dihydrofolate reductase), 2.5 mgml 1 blasticidin for blasticidin deaminase and
125 mgml 1 G418 for the neomycin selectable markers.
The following transgenic parasites were used in this study:
 Dd2::PfCDPK5T392A—The Dd2 line with PfCDPK5 allele bearing T392A
mutation seen in Dd2-21R-resistant line. The wild-type allele is replaced with
the mutated allele that also bears a 3HA tag at the C terminus.
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 Dd2attBþ PfATP4wt–The Dd2attB line with the wild-type PfATP4 gene inserted
at the attB site. This line is a merodiploid with two copies of the wild-type
PfATP4.
 Dd2attBþ PfATP6V178I—The Dd2attB line with PfATP4 bearing V178I
mutation inserted at the attB site. This line is a meroheterozygote expressing
both the wild-type and V178I alleles of PfATP4.
 Dd2::PfCDPK5T392AþPfATP4wt—Transgenic Dd2 line bearing T32A mutation
in its PfCDPK5 gene transfected with the same plasmid used to generate
Dd2attBþ PfATP4wt line. The plasmid replicates as an episome.
 Dd2::PfCDPK5T392AþPfATP4V178I—Transgenic Dd2 line bearing T392A muta-
tion in its PfCDPK5 gene transfected with the same plasmid used to generate the
Dd2attBþ PfATP4V178I line. The plasmid replicates as an episome.
Spectrofluorometer measurements of [Naþ ]i, [Ca2þ ]i and pHi. Trophozoite-
stage, 3D7 P. falciparum parasites (36–40 h post invasion) were functionally iso-
lated from their host erythrocytes by treatment with saponin (0.05% w/v, equating
to 0.005% w/v of the active agent sapogenin) and then loaded with the appropriate
fluorescent probe (Sodium-binding BenzoFuran Isophthalate for [Naþ ]i; BCECF-
AM, 20 ,70-bis-(2-carboxyethyl)-5,6-carboxyfluorescein, acetoxymethyl ester for
pHi; Fura-2, 2-(6-(bis(2-((acetyloxy)methoxy)-2-oxoethyl)amino)-5-(2-(bis(2-
((acetyloxy)methoxy)-2-oxoethyl)amino)-5-methylphenoxy)ethoxy)-2-benzofur-
anyl) for [Ca2þ ]i) and suspended in a medium containing 125mM NaCl, 5mM
KCl, 25mM HEPES, 20mM glucose and 1mM MgCl2; pH 7.10. For the Fura-2/
[Ca2þ ]i experiments, this solution was supplemented with 1mM EGTA and
sufficient CaCl2 to result in a final free extracellular Ca2þ concentration of 1 mM.
Detailed methods for dye-loading, cell concentrations, calibration, rate calculations
and appropriate ratiometric measurement using a spectrofluorometer were as
described in ref. 10. Calibrations were performed for each experiment and are
shown in Supplementary Fig. 13 along with the equations used for assessing ion
concentrations.
Live cell imaging. P. falciparum line 3D7 parasites were synchronized through
osmotic lysis of late-stage parasites incubated with 500mM alanine. Parasitized
erythrocytes in phenol red-free medium were attached to a glass-bottom Petri dish
coated with concanavalin A. Images were obtained in an inverted Nikon Eclipse
microscope equipped with a chamber stage in which temperature (37 C) and gas
mixture (5% O2, 5% CO2 and 95% N2) were maintained. For time-lapse movies,
images were collected every 30min for 45 h using autofocus setting by a  100
objective lens in phase contrast. Images were processed and assembled into videos
using the ImageJ software. Static phase-contrast images of trophozoite-stage
parasites either untreated or treated with 10 nM PA21A050 were obtained after 2-h
incubation under the inverted Nikon microscope. The ImageJ software was used to
measure diameters of untreated and treated parasite images assuming the ery-
throcyte diameter to be 8 mm.
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